Pre-clinical assessment of ALY688 in a mouse model of Duchenne muscular dystrophy

Duchenne muscular dystrophy is a debilitating disease that causes weakness in muscles the move the body as well as the diaphragm. This disease results in severe immobility and can make it difficult to breathe. Strong anti-inflammatories are often prescribed to patients, but the side effects and limited effectiveness underscores the need for developing additional therapies. This research project will determine if a novel anti-inflammatory will increase muscle strength, size and quality (less fibrosis or scar tissue) by lowering inflammation and improving cellular metabolism. By partnering with Allysta Pharmaceuticals Inc. we will test the compound ALY688 in mice that have the same genetic mutation as people with Duchenne muscular dystrophy. If the drug is successful in improving muscle function, the findings may help guide the development of new medicines to help improve the lives of people with this severe disease.

Faculty Supervisor:

Christopher Perry

Student:

Partner:

Allysta

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

York University

Program: